Search results for "Gastroenterologia"

showing 10 items of 310 documents

The production of the oral mucosa of antiendomysial and anti-tissue-transglutaminase antibodies in patients with celiac disease: a review.

2010

Celiac disease (CD) is a lifelong, T cell—mediated enteropathy, triggered by the ingestion of gluten and related prolamins in genetically susceptible subjects, resulting in minor intestinal mucosal injury, including villous atrophy with crypt hyperplasia and intraepithelial lymphocytosis, and subsequent nutrient malabsorption. Although serological tests for antiendomysial (EMA) and anti—tissue transglutaminase (anti-tTG) autoantibodies are used to screen and follow up on patients with CD, diagnostic confirmation is still based on the histological examination of the small intestinal mucosa. Although the small intestinal mucosa is the main site of the gut involved in CD, other mucosal surface…

medicine.medical_specialtySettore MED/09 - Medicina InternaMalabsorptionGlutensTissue transglutaminaseBiopsyantiendomysial antibodieslcsh:Medicineoral biopsyReview Articlelcsh:TechnologyGastroenterologySensitivity and SpecificityGeneral Biochemistry Genetics and Molecular BiologySettore MED/28 - Malattie Odontostomatologicheanti–tissue transglutaminase antibodiesInternal medicineBiopsymedicineHumansEnteropathyOral mucosalcsh:ScienceGeneral Environmental ScienceAutoantibodiesSettore MED/12 - GastroenterologiaGastrointestinal tractTransglutaminasesbiologymedicine.diagnostic_testoral mucosalcsh:Tbusiness.industrylcsh:RMouth MucosaMuscle SmoothGeneral Medicinemedicine.diseaseCeliac Diseasemedicine.anatomical_structureceliac disease oral mucosa anti–tissue transglutaminase antibodies antiendomysial antibodies oral biopsy.Immunologybiology.proteinIntraepithelial lymphocytelcsh:QGliadinbusinessTheScientificWorldJournal
researchProduct

Delayed-Onset Superior Mesenteric Artery Syndrome Presenting as Oesophageal Peptic Stricture

2012

Superior mesenteric artery (SMA) syndrome is an infrequent cause of vomiting and weight loss due to compression of the third part of the duodenum by the SMA. We describe the case of a 17-year-old woman, admitted to our department for progressive dysphagia and severe weight loss due to an oesophageal peptic stricture, caused by chronic acid reflux secondary to duodenal compression by the SMA. Symptoms improved after (par)enteral nutrition and repeated oesophageal dilatation, thus supporting the role of intensive medical and endoscopic intervention as an alternative to surgery, at least in some cases.

medicine.medical_specialtySettore MED/09 - Medicina InternaPepticGastroenterologymedicine.arteryInternal medicinemedicineOesophageal dilatationSuperior mesenteric arterySuperior mesenteric artery syndromelcsh:RC799-869Settore MED/12 - Gastroenterologiabusiness.industryGastroenterologymedicine.diseaseSMA*DysphagiaParenteral nutritionmedicine.anatomical_structureVomitingDuodenumlcsh:Diseases of the digestive system. Gastroenterologymedicine.symptomPublished online: March 2012businessSuperior mesenteric artery syndromeChronic acid refluxCase Reports in Gastroenterology
researchProduct

Screening of colorectal cancer: present and future

2017

Colorectal cancer (CRC) is the third most common cancer in males and second in females, and the fourth most common cause of cancer death worldwide. Currently, about 60-70% of diagnosed cases in symptomatic patients are detected at an advanced stage of disease. Earlier stage detection through the use of screening strategies would allow for better outcomes in terms of reducing the disease burden. Areas covered: The aim of this paper is to review the current published evidence from literature which assesses the performance and effectiveness of different screening tests for the early detection of CRC. Expert commentary: Adequate screening strategies can reduce CRC incidence and mortality. In th…

medicine.medical_specialtyTime FactorsColorectal cancerSettore MED/12 - GASTROENTEROLOGIAEarly detectionDisease03 medical and health sciences0302 clinical medicinemedicineHumansMass ScreeningPharmacology (medical)Stage (cooking)Intensive care medicineEarly Detection of CancerNeoplasm StagingGynecologygFOBTCrc screeningbusiness.industryIncidence (epidemiology)screeningAdvanced stageCancerColonoscopycolonscopymedicine.diseaseFITColorectal cancercolonscopy; Colorectal cancer; FIT; gFOBT; screening; surveillance; Colonoscopy; Colorectal Neoplasms; Early Detection of Cancer; Humans; Mass Screening; Neoplasm Staging; Practice Guidelines as Topic; Time Factors; Oncology; Pharmacology (medical)Oncology030220 oncology & carcinogenesisPractice Guidelines as Topicsurveillance030211 gastroenterology & hepatologybusinessColorectal Neoplasms
researchProduct

The Italian Society of Gastroenterology (SIGE) and the Italian Group for the study of Inflammatory Bowel Disease (IG-IBD) Clinical Practice Guideline…

2010

Biological therapies are an important step in the management of Inflammatory Bowel Diseases. In consideration of high cost and safety issues there is the need to have clear recommendations for their use. Despite the American Gastroenterological Association and the European Crohn's and Colitis Organisation have published exhaustive Inflammatory Bowel Disease guidelines, national guidelines may be necessary as cultural values, economical and legal issues may differ between countries. For these reasons the Italian Society of Gastroenterology and the Italian Group for the study of Inflammatory Bowel Disease have decided to elaborate the Italian guidelines on the use of biologics in Inflammatory…

methods Tumor Necrosis Factor-alphaAnti-Inflammatory AgentsUlcerativeDiseaseGUIDELINESHumanized Antibodieetiology Pregnancy Pregnancy ComplicationGastroenterologyInflammatory bowel diseaseetiology Opportunistic InfectionCrohn DiseasePregnancyNeoplasmsMonoclonaldrug therapy Remission Inductionantagonists /&/ inhibitorsSettore MED/12 - GastroenterologiaRemission InductionGastroenterologyAntibodies MonoclonalUlcerative colitisAnti-Inflammatory AgentItalyadverse effects/therapeutic use Intestinal FistulaTumor necrosis factor alphaFemaleImmunosuppressive Agentsmedicine.drugbiological drugsmedicine.medical_specialtyIBDOpportunistic InfectionsAntibodies Monoclonal HumanizedAutoimmune Diseasesadverse effects/therapeutic use Autoimmune DiseaseInternal medicinemedicineAdalimumabIntestinal FistulaHumansColitisdiagnosis/drug therapy/surgery Italy Neoplasmadverse effects/therapeutic use AntibodieHepatologydrug therapy Female Humans Immunosuppressive Agentbusiness.industryTumor Necrosis Factor-alphaAdalimumabCancermedicine.diseaseInfliximabInfliximabdigestive system diseasesdrug therapy Crohn Diseaseetiology ColitiPregnancy ComplicationsColitis Ulcerativebusiness
researchProduct

Adalimumab in active ulcerative colitis: A “real-life” observational study

2013

Abstract Background and aims The effectiveness of adalimumab in the treatment of ulcerative colitis is under debate. Although controlled trials have shown that adalimumab is significantly better than placebo, the absolute clinical benefit is modest. We report data on the effectiveness of adalimumab in a cohort of ulcerative colitis patients treated in 22 Italian centres. Methods All patients with active disease treated with adalimumab were retrospectively reviewed. Co-primary endpoints were clinical remission at weeks 4, 12, 24 and 54. Secondary endpoints were sustained clinical remission, steroid discontinuation, endoscopic remission and need for colectomy. Results Eighty-eight patients we…

musculoskeletal diseasesAdultMaleAdalimumab “Real-life” study Ulcerative colitismedicine.medical_specialtymedicine.medical_treatmentIBDAnti-Inflammatory AgentsAdalimumab; “Real-life” study; Ulcerative colitisAntibodies Monoclonal HumanizedPlaceboCohort StudiesYoung AdultRefractoryAdrenal Cortex HormonesInternal medicineAdalimumabmedicineHumansskin and connective tissue diseases“Real-life” studyRetrospective StudiesColectomySettore MED/12 - GastroenterologiaHepatologybusiness.industryRemission InductionSettore MED/09 - MEDICINA INTERNAGastroenterologyAdalimumabmedicine.diseaseUlcerative colitishumanitiesInfliximabSurgeryDiscontinuationTreatment OutcomeUlcerative colitisCohortColitis UlcerativeDrug Therapy CombinationFemalebusinessmedicine.drug
researchProduct

Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease

2020

Introduction We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). Methods ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. Results Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. Discussion Once AIH has been ruled out, the long-term outcomes and survival are un…

musculoskeletal diseasesMalemedicine.medical_specialtyAntibodies Antinuclear; Biopsy; England; Female; Humans; Italy; Longitudinal Studies; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Prevalence; Prospective Studies; Survival AnalysisAnti-nuclear antibodyBiopsySettore MED/12 - GASTROENTEROLOGIAAntibodies Antinuclear Biopsy EnglandFemale Humans Italy Longitudinal Studies Male Middle Aged Non-alcoholic Fatty Liver Disease Prevalence Prospective StudiesSurvival AnalysisAutoimmune hepatitisMalignancyGastroenterologyAntibodies03 medical and health sciences0302 clinical medicineimmune system diseasesNon-alcoholic Fatty Liver DiseaseInternal medicineAntinuclearBiopsyNonalcoholic fatty liver diseasemedicineCarcinomaPrevalenceHumansLongitudinal StudiesProspective Studiesskin and connective tissue diseasesProspective cohort studySurvival analysisHepatologymedicine.diagnostic_testbusiness.industryGastroenterologyMiddle Agedmedicine.diseaseSurvival Analysisdigestive system diseases3. Good healthstomatognathic diseasesn/aEnglandItaly030220 oncology & carcinogenesisAntibodies Antinuclear030211 gastroenterology & hepatologyFemalebusiness
researchProduct

EVALUATING THE RISK OF HEPATITIS B REACTIVATION IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES: IS THE SERUM HEPATITIS B PROFILE RELIABLE?

2009

Background/Aim: Patients with an occult hepatitis B virus (HBV) infection undergoing deep immunosuppression are potentially at risk of HBV reactivation. In order to assess whether a polymerase chain reaction (PCR) assay for HBV DNA in serum could be used to predict the reactivation of an occult HBV infection, we performed a retrospective study in a cohort of Sicilian patients with oncohaematological diseases. Methods: We studied by a highly sensitive ad hoc nested PCR for serum HBV DNA 75 HBsAg-negative oncohaematological patients requiring chemotherapy. Results: Thirty-three patients (44%) were HBV seronegative (anti-HBc and anti-HBs negative) and 42 patients (56%) were HBV seropositive (a…

nested PCRSettore MED/07 - Microbiologia E Microbiologia ClinicaSettore MED/12 - GastroenterologiaIMMUNOSUPPRESSIONSettore MED/09 - Medicina InternaHBsAg SEROREVERSIONOBI
researchProduct

MBOAT7 locus rs641738 variant predisposes to hepatocellular carcinoma in nonalcoholic fatty liver

2016

nonalcoholic fatty liver diseaseHepatologyHepatocellular carcinomabusiness.industrySettore MED/12 - GASTROENTEROLOGIAFatty liverGastroenterologyLocus (genetics)medicine.diseaseHepatocellular carcinoma; nonalcoholic fatty liver disease03 medical and health sciences0302 clinical medicineN/A030220 oncology & carcinogenesisHepatocellular carcinomaNonalcoholic fatty liver diseasemedicineCancer research030211 gastroenterology & hepatologybusinessDigestive and Liver Disease
researchProduct

Liver disease severity and low bone mineral density in HIV mono-infected and HIV/HCV co-infected patients

2014

Background: In this study we assess: prevalence of osteopenia, osteoporosis and reduced bone mineral density in HIV infection and HIV / HCV co-infection;risk factors associated with reduced bone mineral density(BMD); relationship between bone mineral density and reduced liver fibrosis (FE) measured as "liver stiffness" (LS), by FibroScan ® in patients co-infected with HIV / HCV; relationship between reduced bone mineral density and cardiovascular risk assessed with the 10-year Framingham risk score (FRS) in HIV / HCV co-infected Patients And Methods: One hundred and ninety-four HIV-infected subjects (121 males =62% and 73 females = 38 %): 129 HIV-infected ( 66.5 % ) and 65 HIV / HCV co-infe…

osteoporosis Liver diseaseSettore MED/12 - GastroenterologiaSettore MED/09 - Medicina InternaSettore MED/17 - Malattie InfettiveSettore MED/42 - Igiene Generale E ApplicataHIV / HCV co-infected
researchProduct

Hepatocyte transplantation, a step forward?

2019

Hepatocyte transplantation emerged a few decades ago as a possible strategy to overcome some of the limitations of liver transplantation, among them the availability of organ donors and the functional quality of grafts. Nowadays, allogenic cell transplantation is still to be confirmed as a viable therapeutic option for patients with hereditary metabolic liver diseases. Although we have now overseen 5 decades of basic and animal research in the field, the number of successfully treated patients remains low. Limitations in cell engraftment and selective proliferation of transplanted cells remain a constraint to the generalized use of this therapeutic approach.

surgical procedures operativeHepatocyte transplantationHepatologybusiness.industryMEDLINEMedicineTrasplantació d'òrgans teixits etc.businessBioinformaticsGastroenterologiaJournal of Hepatology
researchProduct